Brought to you by 
Regado Biosciences nets $43.4mm through its IPO
03 Jun 2021
Executive Summary
Regado Biosciences Inc. (anti-thrombotic drug systems) netted $43.4mm through the initial public offering of 11.67mm common shares (including the overallotment) at $4. Shortly after filing the company announced plans to sell 5mm shares at $14-16 each, but just weeks before pricing, the company said it would sell 8.4mm shares at $5. Existing shareholders bought 7.9mm of the IPO shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Regado Biosciences nets $43.4mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice